Bayesian efficient safety monitoring: a simple and well-performing framework to continuous safety monitoring of adverse events in randomized clinical trials.

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Liangcai Zhang, Ming Chen, Vladimir Dragalin, Bin Eddy Jia, Cunyi Wang, Leixin Xia, Chaohui Yuan, Fei Chen
{"title":"Bayesian efficient safety monitoring: a simple and well-performing framework to continuous safety monitoring of adverse events in randomized clinical trials.","authors":"Liangcai Zhang, Ming Chen, Vladimir Dragalin, Bin Eddy Jia, Cunyi Wang, Leixin Xia, Chaohui Yuan, Fei Chen","doi":"10.1080/10543406.2025.2456176","DOIUrl":null,"url":null,"abstract":"<p><p>During randomized controlled trials, it is critical to remain vigilant in safety monitoring. A common approach is to present information over time, such as frequency tables and graphs, when analyzing adverse events. Nevertheless, there is still a need for developing statistical methods for analyzing safety data of a dynamic nature. The process is typically challenging due to small sample sizes, a lack of observational data sources, difficulties in false-positive control, and the necessity for early detection of serious adverse events. In this article, we propose a simple and effective framework called Bayesian Efficient sAfety Monitoring (BEAM) to analyze evidence aggregation of potentially serious adverse events that may arise during the trial, as well as a timeline for when concrete evidence for safety concerns of unlikely outcomes becomes available. BEAM can be easily tabulated and visualized before the trial starts, making evaluations transparent and easy to use in practice, while maintaining flexibility when the underlying adverse event rate varies. Simulation studies have shown that BEAM supports continuous monitoring, can incorporate external information, and demonstrates good operating characteristics across various scenarios. In most practical situations, it has a reasonable likelihood of detecting elevated risks and identifying safety signals early on when safety concerns arise regarding the investigational drug.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-12"},"PeriodicalIF":1.2000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2456176","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

During randomized controlled trials, it is critical to remain vigilant in safety monitoring. A common approach is to present information over time, such as frequency tables and graphs, when analyzing adverse events. Nevertheless, there is still a need for developing statistical methods for analyzing safety data of a dynamic nature. The process is typically challenging due to small sample sizes, a lack of observational data sources, difficulties in false-positive control, and the necessity for early detection of serious adverse events. In this article, we propose a simple and effective framework called Bayesian Efficient sAfety Monitoring (BEAM) to analyze evidence aggregation of potentially serious adverse events that may arise during the trial, as well as a timeline for when concrete evidence for safety concerns of unlikely outcomes becomes available. BEAM can be easily tabulated and visualized before the trial starts, making evaluations transparent and easy to use in practice, while maintaining flexibility when the underlying adverse event rate varies. Simulation studies have shown that BEAM supports continuous monitoring, can incorporate external information, and demonstrates good operating characteristics across various scenarios. In most practical situations, it has a reasonable likelihood of detecting elevated risks and identifying safety signals early on when safety concerns arise regarding the investigational drug.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信